Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

JUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications, diverse commercial applications, today announced a significant expansion of its collaboration with Fermbox Bio, a biotech research & manufacturing company developing and delivering sustainable bio-based products through precision fermentation and advanced biotechnology tools. This expanded partnership broadens the range of products, platforms, and commercial opportunities the companies will jointly deliver to market. Building on their longstanding relationship, this agreement enables Fermbox Bio to manufacture and commercialize an expanding portfolio of Dyadic-developed proteins and enzymes using both the Dapibus™ and C1 expression systems. Dyadic will co-commercialize these products globally, strengthening its capacity to bring scalable, animal-free solutions to life science, food and nutrition, and bioindustrial sectors.